Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × avelumab × Breast × Clear all

Phase

Phase 2 10 Phase 1/2 8 Phase 1 6 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5 Gynecologic 4 Thoracic 3 Head & Neck 2 Gastrointestinal 2 Tumor-Agnostic 1 Lymphoid 1 Dermatologic 1 Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Cyclophosphamide 171 Docetaxel 163 Paclitaxel 160 Trastuzumab 150 Capecitabine 130 Tamoxifen 119 Letrozole 104 Epirubicin 93 Doxorubicin 83 Anastrozole 82 exemestane 76 Fulvestrant 75 Carboplatin 64 Fluorouracil 63 Radiotherapy 59 pertuzumab 58 Gemcitabine 55 Vinorelbine 43 Goserelin 39 eribulin 36 130-nm albumin-bound paclitaxel 36 palbociclib 32 Bevacizumab 32 ribociclib 30 Zoledronic Acid 29 Lapatinib 29 Methotrexate 28 Chemotherapy, Adjuvant 28 Drug Therapy 27 abemaciclib 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02926196 2025-12-12

A-Brave

Istituto Oncologico Veneto IRCCS

Phase 3 Completed

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡